Phaseline

Companies › Multitude Therapeutics

Multitude Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 7 registered trials: 5 Phase 1, 2 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AMT-116
Antibody-drug conjugate
–Phase 2NSCLC (Advanced Non-small Cell Lung Cancer); Advanced Solid Tumors; Advanced Solid Tumor; Advanced Non-small Cell Lung Cancer (NSCLC)Dec 2026
AMT-676–Phase 2Colorectal CancerSep 2027
AMT-253–Phase 1Advanced Solid TumorDec 2026
AMT-253–Phase 1Malignant MelanomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06782334AMT-116Phase 1Advanced Solid TumorsOncologyDec 2026
NCT05725291AMT-116Phase 1Advanced Solid TumorOncologyDec 2026
NCT05906862AMT-253Phase 1Advanced Solid TumorOncologyDec 2026
NCT06209580AMT-253Phase 1Malignant MelanomaOncologyDec 2026
NCT07590531AMT-116Phase 1Advanced Non-small Cell Lung Cancer (NSCLC)OncologyMay 2027
NCT07474727AMT-676Phase 2Colorectal CancerOncologySep 2027
NCT07718737AMT-116Phase 2NSCLC (Advanced Non-small Cell Lung Cancer)OncologyMar 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Avistone Biotechnology Jacobio Pharmaceuticals Tianjin ConjuStar Biologics DualityBio TORL Biotherapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.